GBA1-associated Parkinson’s disease research hub

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

This study tests a new medicine called VQ-101 for people with Parkinson’s disease linked to an altered gene called GBA1. Researchers want to see if this daily tablet slows down Parkinson’s symptoms and checks how safe it is compared with a dummy pill over 78 weeks.